Indication
Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
Loading your page…
Loading your page…
Dermatitis, Atopic
Marketing Authorisation Holder: LEO Pharma A/S
EMA Authorisation: 17/06/2021
INN: tralokinumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Adtralza: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.